Novartis buys Fougera for $1.5 billion cash to boost Sandoz dermatology business
This article was originally published in Scrip
Novartis will pay $1.5 billion in cash to acquire the private, specialized US firm Fougera Pharmaceuticals and make its generics division Sandoz the number one generic dermatology medicines company in the world with an estimated $620 million in annual global sales.
You may also be interested in...
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.